EULAV Asset Management Makes New $1.67 Million Investment in Prestige Consumer Healthcare Inc. (NYSE:PBH)

EULAV Asset Management acquired a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 19,400 shares of the company's stock, valued at approximately $1,668,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Geode Capital Management LLC boosted its holdings in shares of Prestige Consumer Healthcare by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 1,348,745 shares of the company's stock worth $105,342,000 after purchasing an additional 21,951 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC purchased a new position in shares of Prestige Consumer Healthcare in the 4th quarter worth about $84,932,000. Invesco Ltd. boosted its holdings in shares of Prestige Consumer Healthcare by 2.4% in the 4th quarter. Invesco Ltd. now owns 1,060,263 shares of the company's stock worth $82,796,000 after purchasing an additional 24,392 shares in the last quarter. Congress Asset Management Co. boosted its holdings in shares of Prestige Consumer Healthcare by 9.1% in the 1st quarter. Congress Asset Management Co. now owns 991,580 shares of the company's stock worth $85,246,000 after purchasing an additional 82,838 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in shares of Prestige Consumer Healthcare by 10.9% in the 4th quarter. Northern Trust Corp now owns 813,076 shares of the company's stock valued at $63,493,000 after acquiring an additional 80,055 shares during the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PBH has been the subject of a number of recent research reports. Wall Street Zen raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. Royal Bank Of Canada raised Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $93.33.

Prestige Consumer Healthcare Trading Down 1.7%

PBH traded down $1.31 during midday trading on Thursday, reaching $77.55. 640,050 shares of the company's stock traded hands, compared to its average volume of 309,596. The firm has a fifty day moving average of $84.02 and a two-hundred day moving average of $82.38. The stock has a market capitalization of $3.83 billion, a price-to-earnings ratio of 18.08, a P/E/G ratio of 2.36 and a beta of 0.43. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.20 and a quick ratio of 2.82. Prestige Consumer Healthcare Inc. has a 52 week low of $64.94 and a 52 week high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $1.32 EPS for the quarter, beating analysts' consensus estimates of $1.30 by $0.02. The business had revenue of $296.52 million during the quarter, compared to analyst estimates of $289.36 million. Prestige Consumer Healthcare had a return on equity of 12.87% and a net margin of 18.86%. Prestige Consumer Healthcare's quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.02 EPS. On average, equities analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.